# Explainable Ensemble Learning for Parkinson's Disease Motor Progression Prediction

[![Python](https://img.shields.io/badge/Python-3.11-blue.svg)](https://www.python.org/)
[![Machine Learning](https://img.shields.io/badge/ML-Ensemble-green.svg)](https://scikit-learn.org/)
[![SHAP](https://img.shields.io/badge/XAI-SHAP-orange.svg)](https://github.com/slundberg/shap)
[![Dataset](https://img.shields.io/badge/Data-PPMI-red.svg)](https://www.ppmi-info.org/)

> A SHAP-based explainable machine learning framework for predicting 12-month motor progression in Parkinson's disease using baseline blood transcriptomics and clinical data.

---

## üìã Table of Contents

- [Overview](#overview)
- [Key Features](#key-features)
- [Performance Metrics](#performance-metrics)
- [Repository Structure](#repository-structure)
- [Installation](#installation)
- [Quick Start](#quick-start)
- [Usage Examples](#usage-examples)
- [Model Architecture](#model-architecture)
- [SHAP Analysis](#shap-analysis)
- [Citation](#citation)
- [Contact](#contact)

---

## üî¨ Overview

Parkinson's disease (PD) exhibits significant heterogeneity in motor progression rates across patients. This project presents an **explainable stacking ensemble framework** that integrates:

**Data Sources:**
- **Blood-based transcriptomics** (RNA-seq from PPMI dataset)
- **Clinical features** (baseline UPDRS Part III, age, gender)
- **PD risk genes** (SNCA, LRRK2, GBA, PRKN, PINK1, PARK7, VPS35)
- **Biological pathways** (mitochondrial dysfunction, neuroinflammation, autophagy)
- **Gene-clinical interactions** (e.g., UPDRS_BL √ó PINK1)

**Model Output:**
- Predicts **12-month motor outcomes (UPDRS Part III scores)**
- Achieves **R¬≤=0.551** and **MAE=6.01** on independent clinical test set
- Provides **SHAP-based explanations** for individual predictions

### Key Findings

1. **UPDRS_BL √ó PINK1 interaction** is the strongest predictor (mean |SHAP|=0.283)
2. **Mitochondrial dysfunction** pathway shows highest contribution among biological processes (mean |SHAP|=0.008)
3. **VPS35** is the most important individual PD risk gene (mean |SHAP|=0.010)
4. **Baseline UPDRS** alone has mean |SHAP|=0.258, but interaction with PINK1 increases predictive power

---

## ‚ú® Key Features

### Machine Learning Architecture
- **Stacking Ensemble** with 3 gradient boosting base models:
  - XGBoost (extreme gradient boosting)
  - LightGBM (light gradient boosting machine)
  - CatBoost (categorical boosting)
- **Huber Regressor** meta-learner for robustness to outliers
- **Bayesian hyperparameter optimization** using Optuna (30 trials)
- **7-fold cross-validation** for robust performance estimation
- **Stratified train-test split** (80/20) based on progression status

### Explainability & Interpretability
- **SHAP (SHapley Additive exPlanations)** for feature importance quantification
- **Three-panel SHAP analysis**:
  - Clinical features & interactions
  - PD risk genes
  - Biological pathway scores
- **Gene-clinical interaction effects** explicitly modeled and explained
- **Biological interpretation** linking predictions to known PD mechanisms

### Clinical Decision Support
- **Interactive prediction tool** for individual patients
- **Risk categorization**: Stable, Mild, Moderate, Rapid progression
- **95% confidence intervals** for predictions
- **Minimal input requirements**: Only baseline UPDRS, age, and gender needed
- **Batch processing** capability for multiple patients

---

## üìä Performance Metrics

### Independent Clinical Test Set (n=78)

| Metric | Value | Clinical Interpretation |
|--------|-------|------------------------|
| **R¬≤ Score** | **0.551** | Explains 55.1% of variance in 12-month motor outcomes |
| **MAE** | **6.01** | Average prediction error of 6 UPDRS points |
| **RMSE** | **7.21** | Root mean squared error |
| **Pearson r** | **0.74** | Strong correlation between predicted and actual scores |

### 7-Fold Cross-Validation (n=312)

| Metric | Value |
|--------|-------|
| **R¬≤ Score** | 0.513 ¬± 0.052 |
| **MAE** | 6.15 ¬± 0.25 |
| **RMSE** | 7.86 ¬± 0.57 |

### Clinical Significance

- **MAE=6.01 points** is clinically meaningful (UPDRS Part III range: 0-108)
- **Minimal clinically important difference (MCID)** for UPDRS Part III: ~5 points
- Model predictions enable **personalized risk stratification** for treatment planning
- **Baseline-only approach** allows immediate prognostic assessment at diagnosis

---

## üìÅ Repository Structure

```
.
‚îú‚îÄ‚îÄ parkinson_optimized_model_package/
‚îÇ   ‚îú‚îÄ‚îÄ codes/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ lightweight_optimization.py          # Main training script
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ generate_cv_predictions.py           # Cross-validation predictions
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ predict_new_patient.py               # Prediction for new patients
‚îÇ   ‚îú‚îÄ‚îÄ data/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ example_data.csv                     # Example patient data
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ shap_values_real.csv                 # SHAP values for all features
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ feature_importance_top20.csv         # Top 20 feature importance
‚îÇ   ‚îú‚îÄ‚îÄ model/
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ lightweight_optimized_model.pkl      # Trained ensemble model (582 KB)
‚îÇ   ‚îú‚îÄ‚îÄ results/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ lightweight_optimization_results.csv # Model performance metrics
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ lightweight_cv_detailed.csv          # Detailed CV results
‚îÇ   ‚îú‚îÄ‚îÄ visualization/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ create_figure1_6panels.py            # Main figure generation
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ create_shap_500dpi.py                # SHAP visualization
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ plot_shap_three_panel_clinical.py    # 3-panel SHAP analysis
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ plot_feature_importance.py           # Feature importance plots
‚îÇ   ‚îî‚îÄ‚îÄ documentation/
‚îÇ       ‚îî‚îÄ‚îÄ model_documentation.md               # Detailed model documentation
‚îÇ
‚îî‚îÄ‚îÄ Parkinson_Clinical_Decision_Support/
    ‚îú‚îÄ‚îÄ scripts/
    ‚îÇ   ‚îî‚îÄ‚îÄ predict_patient.py                   # Clinical prediction tool
    ‚îú‚îÄ‚îÄ examples/
    ‚îÇ   ‚îî‚îÄ‚îÄ example_patients.csv                 # Example patient data
    ‚îú‚îÄ‚îÄ results/
    ‚îÇ   ‚îî‚îÄ‚îÄ test_predictions.csv                 # Example predictions
    ‚îî‚îÄ‚îÄ docs/
        ‚îú‚îÄ‚îÄ USER_GUIDE.md                        # Comprehensive user guide
        ‚îî‚îÄ‚îÄ TECHNICAL_DETAILS.md                 # Technical documentation
```

---

## üöÄ Installation

### Prerequisites

- **Python 3.11** or higher
- **Operating System**: Windows, macOS, or Linux
- **RAM**: Minimum 4 GB (8 GB recommended for training)
- **Disk Space**: ~1 GB

### Step 1: Clone Repository

```bash
git clone https://github.com/yeldafrt/PD-Blood-Transcriptomics-SHAP.git
cd PD-Blood-Transcriptomics-SHAP
```

### Step 2: Install Dependencies

```bash
pip install -r requirements.txt
```

**Required packages:**
```
pandas >= 2.0.0
numpy >= 1.24.0
scikit-learn >= 1.3.0
xgboost >= 2.0.0
lightgbm >= 4.0.0
catboost >= 1.2.0
shap >= 0.42.0
optuna >= 3.3.0
matplotlib >= 3.7.0
seaborn >= 0.12.0
joblib >= 1.3.0
```

---

## üèÉ Quick Start

### Option 1: Interactive Prediction (Single Patient)

```bash
cd Parkinson_Clinical_Decision_Support/scripts
python predict_patient.py --interactive
```

**Example interaction:**

```
INTERACTIVE PATIENT PREDICTION MODE
====================================================================

Please enter patient baseline data:

Patient ID (optional): PATIENT_001
Baseline UPDRS Part III score (required): 20
Age in years (required): 68
Gender (0=Female, 1=Male, required): 1

üîÆ Making prediction...

PREDICTION RESULTS
====================================================================

Patient ID: PATIENT_001
Baseline UPDRS Part III: 20.0

Predicted UPDRS at 12 months: 26.5
   95% Confidence Interval: [20.5, 32.5]

Predicted Change: +6.5 points
Progression Risk: Moderate Progression

Clinical Interpretation:
   Moderate progression expected (6.5 points). 
   Consider treatment adjustment and closer monitoring.
====================================================================

Save results to file? (y/n): y
‚úÖ Results saved to: results/prediction_PATIENT_001.csv
```

### Option 2: Batch Prediction from CSV

1. **Prepare patient data** (`patients.csv`):

```csv
PATNO,UPDRS_BL,AGE,GENDER
PATIENT_001,20.0,68.0,1.0
PATIENT_002,25.0,72.0,0.0
PATIENT_003,10.0,55.0,1.0
```

2. **Run batch prediction:**

```bash
python predict_patient.py --input patients.csv --output predictions.csv
```

3. **View results** in `results/predictions.csv`:

```csv
PATNO,UPDRS_BL,AGE,GENDER,PREDICTED_UPDRS_12M,PREDICTED_CHANGE,LOWER_BOUND,UPPER_BOUND,PROGRESSION_RISK
PATIENT_001,20.0,68.0,1.0,26.5,6.5,20.5,32.5,Moderate Progression
PATIENT_002,25.0,72.0,0.0,27.0,2.0,21.0,33.0,Stable
PATIENT_003,10.0,55.0,1.0,17.1,7.1,11.1,23.1,Moderate Progression
```

---

## üíª Usage Examples

### Python API for Custom Integration

```python
import joblib
import pandas as pd
import numpy as np

# Load trained model package
model_package = joblib.load('parkinson_optimized_model_package/model/lightweight_optimized_model.pkl')

# Prepare patient data
patient_data = {
    'PATNO': 'PATIENT_001',
    'UPDRS_BL': 20.0,
    'AGE': 68.0,
    'GENDER': 1.0  # 0=Female, 1=Male
}

# Extract model components
model = model_package['ensemble_model']
scaler = model_package['scaler']
target_transformer = model_package['target_transformer']
feature_names = model_package['feature_names']

# Create feature vector (impute missing features with 0)
patient_df = pd.DataFrame([patient_data])
for feature in feature_names:
    if feature not in patient_df.columns:
        patient_df[feature] = 0.0

patient_df = patient_df[feature_names]

# Scale features and make prediction
X_patient = patient_df.values
X_patient_scaled = scaler.transform(X_patient)
y_pred_trans = model.predict(X_patient_scaled)

# Inverse transform to UPDRS scale
y_pred_updrs = target_transformer.inverse_transform(
    y_pred_trans.reshape(-1, 1)
).flatten()[0]

# Calculate predicted change
predicted_change = y_pred_updrs - patient_data['UPDRS_BL']

print(f"Predicted UPDRS at 12 months: {y_pred_updrs:.1f}")
print(f"Predicted change: {predicted_change:+.1f} points")

# Categorize progression risk
if predicted_change < 3:
    risk = "Stable"
elif predicted_change < 6:
    risk = "Mild Progression"
elif predicted_change < 10:
    risk = "Moderate Progression"
else:
    risk = "Rapid Progression"

print(f"Progression risk: {risk}")
```

### SHAP Explanation for Individual Prediction

```python
import shap

# Load SHAP explainer (if available in model package)
explainer = model_package.get('shap_explainer')

if explainer is None:
    # Create new explainer
    explainer = shap.Explainer(model, X_patient_scaled)

# Calculate SHAP values
shap_values = explainer(X_patient_scaled)

# Visualize feature contributions
shap.waterfall_plot(shap_values[0])
```

---

## üèóÔ∏è Model Architecture

### Stacking Ensemble Framework

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                    STACKING REGRESSOR                           ‚îÇ
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇ                                                                 ‚îÇ
‚îÇ  INPUT: 116 Features                                            ‚îÇ
‚îÇ    ‚îú‚îÄ‚îÄ Clinical (3): UPDRS_BL, AGE, GENDER                     ‚îÇ
‚îÇ    ‚îú‚îÄ‚îÄ Top Genes (100): Selected by correlation with ŒîUPDRS    ‚îÇ
‚îÇ    ‚îú‚îÄ‚îÄ PD Risk Genes (7): SNCA, LRRK2, GBA, PRKN, PINK1,       ‚îÇ
‚îÇ    ‚îÇ                       PARK7, VPS35                         ‚îÇ
‚îÇ    ‚îú‚îÄ‚îÄ Pathways (3): Inflammation, Mitochondrial, Autophagy    ‚îÇ
‚îÇ    ‚îî‚îÄ‚îÄ Interactions (3): PINK1√óPARK7, AGE√óPINK1, UPDRS√óPINK1   ‚îÇ
‚îÇ                                                                 ‚îÇ
‚îÇ  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê   ‚îÇ
‚îÇ  ‚îÇ              LEVEL 0: BASE MODELS                       ‚îÇ   ‚îÇ
‚îÇ  ‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§   ‚îÇ
‚îÇ  ‚îÇ                                                         ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê  ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ  ‚îÇ   XGBoost    ‚îÇ  ‚îÇ  LightGBM    ‚îÇ  ‚îÇ  CatBoost    ‚îÇ  ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ  ‚îÇ              ‚îÇ  ‚îÇ              ‚îÇ  ‚îÇ              ‚îÇ  ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ  ‚îÇ Prediction 1 ‚îÇ  ‚îÇ Prediction 2 ‚îÇ  ‚îÇ Prediction 3 ‚îÇ  ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò  ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ                                                         ‚îÇ   ‚îÇ
‚îÇ  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò   ‚îÇ
‚îÇ                              ‚îÇ                                  ‚îÇ
‚îÇ                              ‚ñº                                  ‚îÇ
‚îÇ  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê   ‚îÇ
‚îÇ  ‚îÇ           LEVEL 1: META-LEARNER                         ‚îÇ   ‚îÇ
‚îÇ  ‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§   ‚îÇ
‚îÇ  ‚îÇ                                                         ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ              Huber Regressor                            ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ         (Robust to outliers)                            ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ                                                         ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ  Optimal linear weighting of base model predictions    ‚îÇ   ‚îÇ
‚îÇ  ‚îÇ                                                         ‚îÇ   ‚îÇ
‚îÇ  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò   ‚îÇ
‚îÇ                              ‚îÇ                                  ‚îÇ
‚îÇ                              ‚ñº                                  ‚îÇ
‚îÇ                                                                 ‚îÇ
‚îÇ  OUTPUT: Predicted UPDRS Part III at 12 months                 ‚îÇ
‚îÇ                                                                 ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

### Training Pipeline

1. **Data Preprocessing**
   - Outlier removal (IQR method)
   - Feature scaling (StandardScaler)
   - Target transformation (Yeo-Johnson)

2. **Feature Selection**
   - Top 100 genes by correlation with ŒîUPDRS
   - 7 PD risk genes (literature-based)
   - 3 pathway scores (biological knowledge)
   - 3 gene-clinical interactions

3. **Hyperparameter Optimization**
   - Bayesian optimization (Optuna)
   - 30 trials per base model
   - 7-fold cross-validation
   - Objective: Minimize MAE

4. **Model Training**
   - Stratified 80/20 train-test split
   - Ensemble stacking with 3 base models
   - Huber meta-learner for final prediction

5. **Validation**
   - Independent clinical test set (n=78)
   - Cross-validation (7 folds, n=312)
   - Performance metrics: R¬≤, MAE, RMSE

---

## üîç SHAP Analysis

### Feature Importance Hierarchy

**Top 10 Features (by mean |SHAP| value):**

| Rank | Feature | Mean \|SHAP\| | Type | Interpretation |
|------|---------|--------------|------|----------------|
| 1 | UPDRS_BL √ó PINK1 | 0.283 | Interaction | Initial severity modulated by PINK1 expression |
| 2 | UPDRS_BL | 0.258 | Clinical | Baseline motor severity |
| 3 | VPS35 | 0.010 | PD Gene | Vesicle trafficking, autophagy dysfunction |
| 4 | Mitochondrial | 0.008 | Pathway | Mitochondrial dysfunction score |
| 5 | GBA | 0.005 | PD Gene | Lysosomal function, Œ±-synuclein clearance |
| 6 | LRRK2 | 0.005 | PD Gene | Kinase activity, autophagy regulation |
| 7 | Neuroinflammation | 0.005 | Pathway | Inflammatory response score |
| 8 | AGE | 0.004 | Clinical | Patient age at baseline |
| 9 | Autophagy | 0.003 | Pathway | Autophagy-lysosome pathway score |
| 10 | GENDER | 0.002 | Clinical | Biological sex |

### Biological Insights

1. **Gene-Clinical Synergy**: The UPDRS_BL √ó PINK1 interaction (SHAP=0.283) exceeds individual contributions, suggesting that initial disease severity is critically modulated by PINK1-mediated mitochondrial quality control.

2. **Mitochondrial Dysfunction**: The mitochondrial pathway score (SHAP=0.008) is the strongest biological process predictor, consistent with established PD pathophysiology.

3. **VPS35 Dominance**: Among PD risk genes, VPS35 (SHAP=0.010) shows the highest importance, highlighting the role of vesicle trafficking and autophagy in progression.

4. **Pathway Hierarchy**: Mitochondrial dysfunction > Neuroinflammation > Autophagy, reflecting the cascade of pathological events in PD progression.

### SHAP Visualization

The repository includes scripts to generate:
- **Summary plots**: Overall feature importance
- **Dependence plots**: Feature-outcome relationships
- **Waterfall plots**: Individual prediction explanations
- **Force plots**: Contribution breakdown for specific patients

---

## üìñ Citation

If you use this code or model in your research, please cite:

```bibtex
@article{firat2025parkinson,
  title={An explainable ensemble machine learning model using baseline blood transcriptomics to predict Parkinson's Disease motor progression},
  author={Fƒ±rat, Yelda and Kƒ±lƒ±√ßaslan, Yƒ±lmaz},
  journal={Parkinsonism and Related Disorders},
  year={2025},
  note={Manuscript submitted for publication}
}
```

**Dataset:**
```bibtex
@misc{ppmi2024,
  title={Parkinson's Progression Markers Initiative Database},
  author={PPMI},
  year={2024},
  howpublished={\url{https://www.ppmi-info.org}},
  note={Accessed: 2024}
}
```

---

## üìß Contact

**Yelda Fƒ±rat**  
Department of Computer Engineering  
Mudanya University, Bursa, Turkey  
Email: yelda.firat@mudanya.edu.tr

**Yƒ±lmaz Kƒ±lƒ±√ßaslan**  
Department of Computer Engineering  
Mudanya University, Bursa, Turkey  
Email: yilmaz.kilicaslan@mudanya.edu.tr

---

## üôè Acknowledgments

This study utilized de-identified data from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org), accessed through the Image and Data Archive (IDA) at LONI (https://ida.loni.usc.edu/). PPMI is sponsored and partially funded by The Michael J. Fox Foundation for Parkinson's Research.

---

## üìù Notes

- This model is intended for **research purposes only** and should not be used for clinical decision-making without appropriate validation.
- The model requires **baseline blood RNA-seq data** for full feature utilization. For clinical use with only UPDRS, age, and gender, prediction accuracy may be reduced.
- **External validation** in independent cohorts is recommended before clinical deployment.
- The code and model are provided "as-is" without warranty of any kind.

---

**Last Updated:** November 2025  
**Version:** 1.0.0  
**Status:** Research - Manuscript Under Review
